TCF20-associated neurodevelopmental disorder is an autosomal dominant condition caused by heterozygous loss of function in TCF20, a chromatin-binding transcriptional co-regulator on 22q13.2. Developmental delay and intellectual disability are fully penetrant, and most patients also have autistic features, attention and hyperactivity problems, and non-specific craniofacial dysmorphism, with variable movement disorder, sleep disturbance, seizures and structural brain anomalies. The disease is a dosage problem rather than a broken-protein problem. TCF20 is among the most loss-of-function-intolerant genes in the genome, its pathogenic variant spectrum is overwhelmingly truncating or whole-gene deletion, and duplications spanning the same gene produce a related disorder with mirror traits. That is the signature of haploinsufficiency rather than of a dominant-negative or neomorphic allele. The molecular context is what makes the phenotype interpretable. TCF20 is the structural relative of RAI1, the Smith-Magenis gene, and the clinical overlap between the two disorders is substantial enough that the original cohort papers describe TAND in those terms. TCF20 sits in a chromatin complex with MeCP2 and PHF14 that co-regulates neuronal genes, and Rett-causing MECP2 mutations disrupt that same interaction. So three separately named neurodevelopmental disorders converge on one chromatin complex, which is a better account of why they resemble each other than any list of shared phenotypes would be.
Ask a research question about TCF20-Associated Neurodevelopmental Disorder. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
Conditions with similar clinical presentations that must be differentiated from TCF20-Associated Neurodevelopmental Disorder:
name: TCF20-Associated Neurodevelopmental Disorder
creation_date: "2026-09-05T10:00:00Z"
category: Mendelian
synonyms:
- TAND
- DDVIBA
- developmental delay with variable intellectual impairment and behavioral abnormalities
- TCF20-related disorder
description: >-
TCF20-associated neurodevelopmental disorder is an autosomal dominant
condition caused by heterozygous loss of function in TCF20, a chromatin-binding
transcriptional co-regulator on 22q13.2. Developmental delay and intellectual
disability are fully penetrant, and most patients also have autistic features,
attention and hyperactivity problems, and non-specific craniofacial
dysmorphism, with variable movement disorder, sleep disturbance, seizures and
structural brain anomalies.
The disease is a dosage problem rather than a broken-protein problem. TCF20 is
among the most loss-of-function-intolerant genes in the genome, its pathogenic
variant spectrum is overwhelmingly truncating or whole-gene deletion, and
duplications spanning the same gene produce a related disorder with mirror
traits. That is the signature of haploinsufficiency rather than of a
dominant-negative or neomorphic allele.
The molecular context is what makes the phenotype interpretable. TCF20 is the
structural relative of RAI1, the Smith-Magenis gene, and the clinical overlap
between the two disorders is substantial enough that the original cohort
papers describe TAND in those terms. TCF20 sits in a chromatin complex with
MeCP2 and PHF14 that co-regulates neuronal genes, and Rett-causing MECP2
mutations disrupt that same interaction. So three separately named
neurodevelopmental disorders converge on one chromatin complex, which is a
better account of why they resemble each other than any list of shared
phenotypes would be.
disease_term:
preferred_term: TCF20-associated neurodevelopmental disorder
term:
id: MONDO:0032745
label: developmental delay with variable intellectual impairment and behavioral abnormalities
parents:
- Neurodevelopmental disorder
- Chromatinopathy
inheritance:
- name: Autosomal dominant inheritance
inheritance_term:
preferred_term: Autosomal dominant inheritance
term:
id: HP:0000006
label: Autosomal dominant inheritance
description: >-
A single inactivating TCF20 allele is sufficient. Most cases are de novo,
about a tenth are inherited from a mildly affected parent, and around one in
twelve arise through germline mosaicism, which is the figure that matters
for recurrence-risk counselling.
de_novo_rate: "~67% de novo; ~10% inherited; ~8% confirmed or suspected germline mosaicism"
evidence:
- reference: PMID:40011607
reference_title: "Germline mosaicism in TCF20-associated neurodevelopmental disorders: a case study and literature review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "To date, a total of 91 individuals with TAND have been reported; ~67% of cases arose de novo, while ~10% were inherited, and, intriguingly, ~8% were either confirmed or suspected to have arisen via germline mosaicism."
explanation: Gives the three inheritance routes and their proportions across the whole reported cohort.
genetic:
- name: TCF20
gene_term:
preferred_term: TCF20
term:
id: hgnc:11631
label: TCF20
association: >-
TCF20 encodes a nuclear chromatin-binding transcriptional co-regulator.
Heterozygous loss of function causes TAND; duplication of the same locus
causes a distinct neurodevelopmental disorder with mirror traits.
relationship_type: CAUSATIVE
evidence:
- reference: PMID:30819258
reference_title: "De novo and inherited TCF20 pathogenic variants are associated with intellectual disability, dysmorphic features, hypotonia, and neurological impairments with similarities to Smith-Magenis syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "TCF20 encodes a transcriptional co-regulator structurally related to RAI1, the dosage-sensitive gene responsible for Smith-Magenis syndrome (deletion/haploinsufficiency) and Potocki-Lupski syndrome (duplication/triplosensitivity)."
explanation: Establishes the gene's identity and the dosage-sensitive paralogue whose disorders frame the expectations for this one.
- reference: PMID:30819258
reference_title: "De novo and inherited TCF20 pathogenic variants are associated with intellectual disability, dysmorphic features, hypotonia, and neurological impairments with similarities to Smith-Magenis syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Genome-wide analyses by exome sequencing (ES) and chromosomal microarray analysis (CMA) identified individuals with heterozygous, likely damaging, loss-of-function alleles in TCF20."
explanation: The ascertainment that established the gene-disease relationship, and the two assays that find the two classes of allele.
- reference: PMID:30819258
reference_title: "De novo and inherited TCF20 pathogenic variants are associated with intellectual disability, dysmorphic features, hypotonia, and neurological impairments with similarities to Smith-Magenis syndrome."
supports: SUPPORT
evidence_source: COMPUTATIONAL
snippet: "TCF20 was predicted to be of higher intolerance to LoF variants as reflected by its higher pLI (probability of LoF intolerance) score (pLI = 1)"
explanation: >-
The population-constraint argument that made TCF20 the candidate in the
first place, and the quantitative basis for expecting haploinsufficiency
rather than a milder dosage effect. Graded COMPUTATIONAL because pLI is a
constraint metric computed over reference cohorts, not a patient
observation.
variants:
- name: TCF20 truncating and whole-gene deletion alleles
description: >-
The reported spectrum is dominated by frameshift and nonsense alleles plus
whole-gene deletions, with missense alleles a small minority. That
distribution is itself the argument for haploinsufficiency.
clinical_significance: PATHOGENIC
evidence:
- reference: PMID:30819258
reference_title: "De novo and inherited TCF20 pathogenic variants are associated with intellectual disability, dysmorphic features, hypotonia, and neurological impairments with similarities to Smith-Magenis syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "To date, a few de novo mutations potentially disrupting TCF20 function in patients with ID, ASD, and hypotonia have been reported."
explanation: The initial variant reports from which the truncating spectrum was subsequently characterized.
- reference: PMID:30819258
reference_title: "De novo and inherited TCF20 pathogenic variants are associated with intellectual disability, dysmorphic features, hypotonia, and neurological impairments with similarities to Smith-Magenis syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "We report 25 unique inactivating single nucleotide variants/indels (1 missense, 1 canonical splice-site variant, 18 frameshift, and 5 nonsense) and 4 deletions of TCF20."
explanation: >-
The class breakdown itself. Twenty-three of 25 point alleles are
frameshift or nonsense and there is a single missense, which is the
distribution the haploinsufficiency argument rests on rather than an
impression of it.
- name: TCF20 c.4737del p.Lys1579Asnfs*36
description: >-
A novel frameshift allele shared by two siblings and absent from both
parents' blood, traced to paternal germline mosaicism detected in
urothelial cells.
clinical_significance: PATHOGENIC
evidence:
- reference: PMID:40011607
reference_title: "Germline mosaicism in TCF20-associated neurodevelopmental disorders: a case study and literature review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "droplet digital PCR (ddPCR) of DNA derived from early morning urine detected the variation in 3.2% of the father's urothelial cells, confirming germline mosaicism"
explanation: Physical confirmation of germline mosaicism, which is what turns an apparently de novo recurrence into a quantifiable recurrence risk.
pathophysiology:
- name: TCF20 Haploinsufficiency
biological_scale: MOLECULAR
description: >-
One inactivated allele halves the dose of a chromatin-binding
transcriptional co-regulator. The reciprocal duplication causing a mirror
disorder is the strongest available argument that dose, rather than a
property of the mutant protein, is what matters.
gene:
preferred_term: TCF20
modifier: LOSS_OF_FUNCTION
term:
id: hgnc:11631
label: TCF20
molecular_functions:
- preferred_term: transcription coactivator activity
modifier: DECREASED
term:
id: GO:0003713
label: transcription coactivator activity
evidence:
- reference: PMID:34904221
reference_title: "Rare and de novo duplications containing TCF20 are associated with a neurodevelopmental disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Duplication including TCF20 was suspected to cause a neurodevelopmental disorder (NDD) with mirror traits compared to patients with TCF20 deletions."
explanation: The mirror-trait duplication disorder, which is what identifies the mechanism as dosage rather than allele-specific.
- reference: PMID:34904221
reference_title: "Rare and de novo duplications containing TCF20 are associated with a neurodevelopmental disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Most pathogenic variants are loss-of-function variants."
explanation: The allele spectrum expected under a haploinsufficiency mechanism.
- reference: PMID:10995766
reference_title: "The nuclear factor SPBP contains different functional domains and stimulates the activity of various transcriptional activators."
supports: SUPPORT
evidence_source: IN_VITRO
directness: INDIRECT
snippet: "Hence, SPBP seems to act as a transcriptional coactivator."
explanation: >-
Grounds the coactivator-activity binding on this node. SPBP is the former
symbol for TCF20, and the cotransfection experiments behind this sentence
are what establish the activity that a halved dose reduces. Indirect
because the work predates both the rename and the disease association.
downstream:
- target: Reduced Occupancy of the MeCP2-PHF14-TCF20 Chromatin Complex
causal_link_type: DIRECT
evidence:
- reference: PMID:35074918
reference_title: "Disruption of MeCP2-TCF20 complex underlies distinct neurodevelopmental disorders."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Using proximity-dependent biotinylation (BioID), we identified a transcription factor 20 (TCF20) complex that interacts with MeCP2 at the chromatin interface."
explanation: Establishes that TCF20 acts as part of a defined complex at chromatin, which is the object a reduced dose acts on.
- name: Reduced Occupancy of the MeCP2-PHF14-TCF20 Chromatin Complex
biological_scale: MOLECULAR
description: >-
TCF20 and MeCP2 are co-expressed in neurons and co-regulate a shared set of
neuronal genes. The complex is the convergence point for three separately
named disorders: Rett-causing MECP2 mutations abolish the interaction from
one side, a PHF14 missense variant abolishes it from another, and TCF20
haploinsufficiency reduces it from a third. TCF20 binds chromatin through
two independent nucleosome-interaction domains, so a halved dose is
plausibly a halved residence on chromatin rather than a qualitatively
altered complex.
molecular_functions:
- preferred_term: chromatin binding
modifier: DECREASED
term:
id: GO:0003682
label: chromatin binding
cell_types:
- preferred_term: neuron
term:
id: CL:0000540
label: neuron
evidence:
- reference: PMID:35074918
reference_title: "Disruption of MeCP2-TCF20 complex underlies distinct neurodevelopmental disorders."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "TCF20 and MeCP2 are highly coexpressed in neurons and coregulate the expression of key neuronal genes."
explanation: Co-expression and co-regulation are what make the complex the functional unit rather than TCF20 alone.
- reference: PMID:35074918
reference_title: "Disruption of MeCP2-TCF20 complex underlies distinct neurodevelopmental disorders."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "We identified a patient exhibiting RTT-like neurological features with a missense mutation in the PHF14 subunit of the TCF20 complex that abolishes the MeCP2-PHF14-TCF20 interaction."
explanation: A third gene reaching a Rett-like phenotype by disrupting the same complex, which is the convergence this node asserts.
- reference: PMID:22081970
reference_title: "Identification of two independent nucleosome-binding domains in the transcriptional co-activator SPBP."
supports: SUPPORT
evidence_source: IN_VITRO
directness: INDIRECT
snippet: "contains two independent chromatin-binding domains, the SPBP-(1551-1666) region and the C-terminal extended PHD"
explanation: Characterizes how the protein engages chromatin. It is indirect because the work predates the disease association and names the protein by its former symbol, SPBP.
downstream:
- target: Dysregulated Neuronal Transcriptional Program
causal_link_type: DIRECT
evidence:
- reference: PMID:39801227
reference_title: "Regulation of Dendrite and Dendritic Spine Formation by TCF20."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "RNA sequencing analysis revealed a downregulation of pre- and postsynaptic pathways in TCF20 knockdown neurons."
explanation: Reducing TCF20 in neurons changes the transcriptional program, measured directly by RNA sequencing.
- name: Dysregulated Neuronal Transcriptional Program
biological_scale: CELLULAR
description: >-
Knockdown of TCF20 in cortical neurons downregulates pre- and postsynaptic
pathways and reduces specific synaptic proteins, with an unexpected
asymmetry: GABRA1, BDNF, PSD-95, c-Fos, GluN2B and GABRA5 fall while GluA2
rises. The mixed direction matters, because it means the consequence is a
reshaped synaptic composition rather than a uniform loss of synaptic gene
expression.
cell_types:
- preferred_term: cortical neuron
term:
id: CL:0000540
label: neuron
biological_processes:
- preferred_term: regulation of transcription by RNA polymerase II
modifier: ABNORMAL
term:
id: GO:0006357
label: regulation of transcription by RNA polymerase II
locations:
- preferred_term: brain
term:
id: UBERON:0000955
label: brain
evidence:
- reference: PMID:39801227
reference_title: "Regulation of Dendrite and Dendritic Spine Formation by TCF20."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "We also found decreased levels of GABRA1, BDNF, PSD-95, and c-Fos in total homogenates and in synaptosomal preparations of knockdown TCF20 rat cortical cultures."
explanation: The specific proteins reduced by TCF20 knockdown.
- reference: PMID:39801227
reference_title: "Regulation of Dendrite and Dendritic Spine Formation by TCF20."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "synaptosomal preparations of knockdown TCF20 rat cortical cultures showed significant downregulation of GluN2B and GABRA5, while GluA2 was significantly upregulated"
explanation: The bidirectional change this node's description turns on.
downstream:
- target: Impaired Dendritic Arborization and Spine Formation
causal_link_type: DIRECT
evidence:
- reference: PMID:39801227
reference_title: "Regulation of Dendrite and Dendritic Spine Formation by TCF20."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Our findings suggest that TCF20 plays a central role in dendritic arborization and dendritic spine formation processes."
explanation: States the structural consequence the transcriptional changes lead to.
- name: Impaired Dendritic Arborization and Spine Formation
biological_scale: CELLULAR
description: >-
The structural endpoint measurable in neurons. TCF20 expression rises
through brain development in mice, which places its requirement in the
period when arbors and spines are being built rather than maintained.
cell_types:
- preferred_term: neuron
term:
id: CL:0000540
label: neuron
biological_processes:
- preferred_term: dendrite development
modifier: ABNORMAL
term:
id: GO:0016358
label: dendrite development
- preferred_term: dendritic spine development
modifier: ABNORMAL
term:
id: GO:0060996
label: dendritic spine development
- preferred_term: synapse organization
modifier: ABNORMAL
term:
id: GO:0050808
label: synapse organization
evidence:
- reference: PMID:39801227
reference_title: "Regulation of Dendrite and Dendritic Spine Formation by TCF20."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "we demonstrate that TCF20 is expressed in all analyzed brain regions in mice, and its expression increases during brain development but decreases in muscle tissue"
explanation: The developmental expression profile that places the requirement in the arborization window.
- reference: PMID:39801227
reference_title: "Regulation of Dendrite and Dendritic Spine Formation by TCF20."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "our data suggest that TCF20 plays an essential role in neuronal development and function by modulating the expression of proteins involved in dendrite and synapse formation and function"
explanation: The authors' own summary of the mechanism this node states.
downstream:
- target: Global Developmental Delay
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
evidence:
- reference: PMID:30739909
reference_title: "Variants in TCF20 in neurodevelopmental disability: description of 27 new patients and review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "To define the clinical characteristics of patients with variants in TCF20, we describe 27 patients, 26 of whom were identified via exome sequencing."
explanation: The cohort in which the clinical endpoint is characterized. The steps between altered dendritic development in culture and the human developmental phenotype are not demonstrated.
- target: Autism
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
evidence:
- reference: PMID:39801227
reference_title: "Regulation of Dendrite and Dendritic Spine Formation by TCF20."
supports: SUPPORT
evidence_source: IN_VITRO
directness: INDIRECT
snippet: "Mutations in the Transcription Factor 20 (TCF20) have been identified in patients with autism spectrum disorders (ASDs), intellectual disabilities (IDs), and other neurological issues."
explanation: Connects the studied molecular function to the autistic phenotype by way of the gene's clinical associations rather than by a demonstrated causal path.
- target: Delayed Speech and Language Development
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
evidence:
- reference: PMID:30739909
reference_title: "Variants in TCF20 in neurodevelopmental disability: description of 27 new patients and review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "with an average age of sitting at 10 months (n=17), walking at 20 months (n=22), and talking at 23 months (n=19), similar to the milestones previously reported"
explanation: >-
The delayed language milestone in the cohort carrying the lesion. As
with the two edges above, the steps from altered dendritic development
in culture to a delayed first word are not demonstrated, which is why
the edge is typed with unknown intermediates.
phenotypes:
- name: Global Developmental Delay
category: Neurodevelopmental
description: >-
Present in every reported patient. Developmental delay and intellectual
disability together form the fully penetrant core of the disorder.
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Global developmental delay
term:
id: HP:0001263
label: Global developmental delay
evidence:
- reference: PMID:30739909
reference_title: "Variants in TCF20 in neurodevelopmental disability: description of 27 new patients and review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "All had developmental delay/intellectual disability."
explanation: Full penetrance across the 27-patient cohort.
- name: Intellectual Disability
category: Neurodevelopmental
description: >-
Typically mild, and universal in reported patients.
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Intellectual disability
term:
id: HP:0001249
label: Intellectual disability
evidence:
- reference: PMID:30739909
reference_title: "Variants in TCF20 in neurodevelopmental disability: description of 27 new patients and review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "All had developmental delay/intellectual disability."
explanation: The same cohort statement, which does not separate the two.
- name: Delayed Speech and Language Development
category: Neurodevelopmental
description: >-
Speech is delayed as part of the developmental phenotype, with an average
age at first words of 23 months. Beyond simple delay, a substantial minority
carry a specific speech-production problem: apraxia or articulation
difficulty rather than a purely language-level deficit. The cohort splits
roughly in three, with 11 of 27 having no speech concern at all, so this is
a frequent feature rather than a universal one.
frequency: FREQUENT
phenotype_term:
preferred_term: Delayed speech and language development
term:
id: HP:0000750
label: Delayed speech and language development
evidence:
- reference: PMID:30739909
reference_title: "Variants in TCF20 in neurodevelopmental disability: description of 27 new patients and review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "There were no speech concerns noted for 11 patients, but significant speech problems including apraxia or articulation difficulties were reported in eight patients."
explanation: >-
Gives both the numerator and the counter-numerator, so the frequency band
is read off the cohort rather than inferred. Eight of 27 with significant
problems places this in the FREQUENT band.
- reference: PMID:30739909
reference_title: "Variants in TCF20 in neurodevelopmental disability: description of 27 new patients and review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "with an average age of sitting at 10 months (n=17), walking at 20 months (n=22), and talking at 23 months (n=19), similar to the milestones previously reported"
explanation: >-
The milestone data behind the delay itself, distinct from the
articulation problem quoted above.
- name: Autism
category: Neurobehavioral
description: >-
Autism spectrum disorder or autistic features in roughly two-thirds of
patients.
frequency: FREQUENT
phenotype_term:
preferred_term: Autism spectrum disorder or autistic features
term:
id: HP:0000717
label: Autism
evidence:
- reference: PMID:30739909
reference_title: "Variants in TCF20 in neurodevelopmental disability: description of 27 new patients and review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Autism spectrum disorders/autistic features were reported in 69%"
explanation: The cohort frequency.
- name: Attention Deficit Hyperactivity Disorder
category: Neurobehavioral
description: >-
Attention problems or hyperactivity in roughly two-thirds of patients.
frequency: FREQUENT
phenotype_term:
preferred_term: Attention disorder or hyperactivity
term:
id: HP:0007018
label: Attention deficit hyperactivity disorder
evidence:
- reference: PMID:30739909
reference_title: "Variants in TCF20 in neurodevelopmental disability: description of 27 new patients and review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "attention disorders or hyperactivity in 67%"
explanation: The cohort frequency.
- name: Hypotonia
category: Neurological
description: >-
Part of the shared core phenotype alongside developmental and motor delay.
frequency: FREQUENT
phenotype_term:
preferred_term: Hypotonia
term:
id: HP:0001252
label: Hypotonia
evidence:
- reference: PMID:34904221
reference_title: "Rare and de novo duplications containing TCF20 are associated with a neurodevelopmental disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The shared core phenotype includes developmental delay, hypotonia, motor delay, autism spectrum disorders, neurobehavioral anomalies"
explanation: Places hypotonia in the shared core rather than among the variable features.
- name: Motor Delay
category: Neurodevelopmental
description: >-
Delayed motor milestones, part of the shared core phenotype.
frequency: FREQUENT
phenotype_term:
preferred_term: Motor delay
term:
id: HP:0001270
label: Motor delay
evidence:
- reference: PMID:34904221
reference_title: "Rare and de novo duplications containing TCF20 are associated with a neurodevelopmental disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The shared core phenotype includes developmental delay, hypotonia, motor delay"
explanation: Motor delay named in the core phenotype.
- name: Abnormal Brain Morphology
category: Neurological
description: >-
Structural brain anomalies on imaging in about a quarter of patients, with
no single characteristic finding.
frequency: OCCASIONAL
phenotype_term:
preferred_term: Structural brain anomaly
term:
id: HP:0012443
label: Abnormal brain morphology
evidence:
- reference: PMID:30739909
reference_title: "Variants in TCF20 in neurodevelopmental disability: description of 27 new patients and review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "structural brain anomalies in 24%"
explanation: The cohort frequency.
- name: Seizure
category: Neurological
description: >-
Seizures in about one in eight patients, so a real but minority feature.
frequency: OCCASIONAL
phenotype_term:
preferred_term: Seizure
term:
id: HP:0001250
label: Seizure
evidence:
- reference: PMID:30739909
reference_title: "Variants in TCF20 in neurodevelopmental disability: description of 27 new patients and review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "structural brain anomalies in 24%, and seizures in 12%"
explanation: The cohort frequency.
- name: Dystonia
category: Neurological
description: >-
Movement disorder including dystonia is part of the reported spectrum, and
in one report dystonia was prominent enough to be the presenting problem.
phenotype_term:
preferred_term: Dystonia
term:
id: HP:0001332
label: Dystonia
evidence:
- reference: PMID:40011607
reference_title: "Germline mosaicism in TCF20-associated neurodevelopmental disorders: a case study and literature review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "a condition characterized by developmental delay and intellectual disability, autism, dysmorphisms, dystonia, and variable other neurological features"
explanation: Dystonia named in the disorder's defining feature list.
- name: Sleep Disturbance
category: Neurobehavioral
description: >-
Sleep problems including circadian rhythm disturbance, which is one of the
features that echoes Smith-Magenis syndrome.
phenotype_term:
preferred_term: Sleep disturbance
term:
id: HP:0002360
label: Sleep disturbance
evidence:
- reference: PMID:40011607
reference_title: "Germline mosaicism in TCF20-associated neurodevelopmental disorders: a case study and literature review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "a developmental condition characterized by intellectual disability, autism, a circadian rhythm sleep disorder, and attention deficit hyperactivity disorder (ADHD)"
explanation: A circadian rhythm sleep disorder documented in two molecularly confirmed siblings.
- name: Craniofacial Dysmorphism
category: Craniofacial
description: >-
Craniofacial features are reported in about two-thirds of patients, but they
do not assemble into a recognizable facial gestalt. That distinction is the
whole clinical point: the finding is common enough to be part of the
phenotype and to appear in the defining paper's title, while being too
unpatterned to support diagnosis by inspection. The binding is deliberately
the generic HP:0001999, since asserting any specific facial feature would
claim structure the source explicitly denies.
frequency: FREQUENT
phenotype_term:
preferred_term: Craniofacial features without a recognizable gestalt
term:
id: HP:0001999
label: Abnormal facial shape
evidence:
- reference: PMID:30739909
reference_title: "Variants in TCF20 in neurodevelopmental disability: description of 27 new patients and review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "craniofacial features (no recognizable facial gestalt) in 67%"
explanation: >-
Carries the frequency and the absence of a gestalt in one sentence, which
is why both are curated together rather than the frequency alone.
- reference: PMID:30739909
reference_title: "Variants in TCF20 in neurodevelopmental disability: description of 27 new patients and review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "craniofacial features were reported in 18/27 (67%) and other minor malformations in 10/27 (37%), but did not appear to constitute a single recognizable or distinct phenotype"
explanation: >-
The count behind the percentage, and the authors' own statement that the
features do not form a distinct phenotype.
treatments:
- name: Early Intervention and Developmental Therapies
description: >-
Physical, occupational and speech therapy from early childhood. There is no
disease-specific or targeted therapy; management addresses the developmental
consequences rather than the transcriptional lesion.
therapeutic_modality: BEHAVIORAL
treatment_term:
preferred_term: Physical Therapy
term:
id: NCIT:C15302
label: Physical Therapy
evidence:
- reference: PMID:30739909
reference_title: "Variants in TCF20 in neurodevelopmental disability: description of 27 new patients and review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "All had developmental delay/intellectual disability."
explanation: The universal developmental phenotype that these therapies address; the cited cohort characterizes the phenotype rather than evaluating the intervention.
target_mechanisms:
- target: Global Developmental Delay
treatment_effect: MODULATES
description: >-
Supportive rather than mechanism-directed. Nothing in the cited literature
evaluates the effect of these therapies in this disorder specifically.
- name: Speech and Language Therapy
description: >-
Speech and language intervention for the communication component of the
developmental phenotype.
therapeutic_modality: BEHAVIORAL
treatment_term:
preferred_term: Speech Language Therapy
term:
id: NCIT:C159273
label: Speech Language Therapy
evidence:
- reference: PMID:30739909
reference_title: "Variants in TCF20 in neurodevelopmental disability: description of 27 new patients and review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "All had developmental delay/intellectual disability."
explanation: The developmental delay that indicates speech intervention. No disorder-specific trial evidence exists.
target_mechanisms:
- target: Delayed Speech and Language Development
treatment_effect: MODULATES
description: >-
The phenotype this therapy is aimed at. Symptomatic, and not evaluated in
this disorder specifically.
- name: Genetic Counseling With Germline Mosaicism Testing
description: >-
Recurrence-risk counselling has a specific technical component here. Around
one in twelve reported cases arose through germline mosaicism, and in the
documented family the variant was undetectable in either parent's blood by
Sanger sequencing and by deep sequencing, and was found only by droplet
digital PCR on urine-derived cells. A negative parental blood test therefore
does not establish a de novo event.
therapeutic_modality: BEHAVIORAL
treatment_term:
preferred_term: Genetic Counseling
term:
id: NCIT:C15240
label: Genetic Counseling
evidence:
- reference: PMID:40011607
reference_title: "Germline mosaicism in TCF20-associated neurodevelopmental disorders: a case study and literature review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The variant was not detected in DNA extracted from peripheral blood in either parent by Sanger sequencing of PCR-generated amplicons, or by deep sequencing of PCR amplicons using MiSeq and MinION."
explanation: Documents that the standard parental tests were negative, which is what makes the counselling caveat concrete.
- reference: PMID:40011607
reference_title: "Germline mosaicism in TCF20-associated neurodevelopmental disorders: a case study and literature review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "This report is only the second to confirm with physical evidence TCF20 germline mosaicism and discusses germline mosaicism as a likely under-detected mode of inheritance in neurodevelopmental conditions."
explanation: The authors' own framing that this mode of inheritance is under-detected, which is the reason to test for it rather than assume it away.
- name: Behavioral Management of Autism and ADHD
description: >-
Behavioural intervention for the autistic and attention phenotypes, which
affect roughly two-thirds of patients each.
therapeutic_modality: BEHAVIORAL
treatment_term:
preferred_term: Behavioral Counseling
term:
id: NCIT:C181743
label: Behavioral Counseling
evidence:
- reference: PMID:30739909
reference_title: "Variants in TCF20 in neurodevelopmental disability: description of 27 new patients and review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Autism spectrum disorders/autistic features were reported in 69%, attention disorders or hyperactivity in 67%"
explanation: The prevalence of the phenotypes this management addresses. The cited work does not evaluate the interventions.
target_mechanisms:
- target: Autism
treatment_effect: MODULATES
description: >-
Symptomatic. Behavioural intervention acts on the expressed phenotype and
not on the transcriptional lesion upstream of it.
- target: Attention Deficit Hyperactivity Disorder
treatment_effect: MODULATES
description: >-
Symptomatic, on the same footing as the autism arm.
- name: Pharmacotherapy for Autism and ADHD Symptoms
description: >-
Medication where the behavioural and attention phenotypes warrant it. This
is separated from the behavioural entry because it is a different modality:
bundling the two under a behavioural-counselling term made the record
contradict its own name. Only one agent is named in a cached source for this
disease, methylphenidate in a single molecularly confirmed patient, so that
is the only `therapeutic_agent` bound. No cached source names an agent for
the autistic phenotype, and none is filled in from general practice.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: methylphenidate
term:
id: CHEBI:6887
label: methylphenidate
evidence:
- reference: PMID:30739909
reference_title: "Variants in TCF20 in neurodevelopmental disability: description of 27 new patients and review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Autism spectrum disorders/autistic features were reported in 69%, attention disorders or hyperactivity in 67%"
explanation: >-
The indication, not an evaluation. The cohort reports the prevalence of
the phenotypes and does not report which patients were medicated or with
what.
- reference: PMID:40011607
reference_title: "Germline mosaicism in TCF20-associated neurodevelopmental disorders: a case study and literature review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "suffers from attention hyperactivity attention disorder (ADHD) which is successfully treated with methylphenidate"
explanation: >-
Names the agent used in this disease and reports it as effective. This is
one molecularly confirmed patient in an uncontrolled case report, so it
supports methylphenidate being used here and carries no frequency or
efficacy claim for the disorder.
target_mechanisms:
- target: Attention Deficit Hyperactivity Disorder
treatment_effect: MODULATES
description: >-
Symptomatic. One case report describes methylphenidate controlling the
attention phenotype; no controlled evaluation exists in this disorder.
- name: Melatonin for Circadian Rhythm Sleep Disorder
description: >-
Melatonin for the circadian rhythm sleep disorder, which is one of the
features that echoes Smith-Magenis syndrome. Reported as effective in a
single molecularly confirmed patient.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: melatonin
term:
id: CHEBI:16796
label: melatonin
evidence:
- reference: PMID:40011607
reference_title: "Germline mosaicism in TCF20-associated neurodevelopmental disorders: a case study and literature review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "She has a circadian rhythm sleep disorder which is successfully controlled with melatonin"
explanation: >-
Names the agent and reports the outcome in this disease. One uncontrolled
patient, so it supports the intervention being used rather than
establishing efficacy or how often it is needed.
target_mechanisms:
- target: Sleep Disturbance
treatment_effect: MODULATES
description: >-
Symptomatic, acting on the circadian phenotype and not on the
transcriptional lesion upstream of it.
- name: Antiseizure Medication
description: >-
Seizures occur in a minority and are managed with standard antiseizure
medication. The cohort documents the full range of outcomes in three
patients: one weaned off after a seizure-free year, one controlled on
medication, and one with refractory generalized epilepsy. No agent is named,
so none is curated.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
evidence:
- reference: PMID:30739909
reference_title: "Variants in TCF20 in neurodevelopmental disability: description of 27 new patients and review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Patient 8 had seizures while sleeping and is treated with medication."
explanation: Direct documentation that antiseizure medication is used in this disorder.
- reference: PMID:30739909
reference_title: "Variants in TCF20 in neurodevelopmental disability: description of 27 new patients and review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Since the age of five, Patient 24 has had multiple types of seizures and a diagnosis of refractory epilepsy/intractable generalized epilepsy."
explanation: >-
The refractory end of the range, which is why the treatment is recorded as
modulating rather than controlling the seizure phenotype.
target_mechanisms:
- target: Seizure
treatment_effect: MODULATES
description: >-
Symptomatic seizure control. One of the three documented patients had
refractory epilepsy, so the effect is not uniform.
diagnosis:
- name: Trio exome sequencing
description: >-
The route by which nearly all reported patients were found. Trio design
matters because most alleles are de novo, and because the alternative,
inheritance from a mildly affected parent, is only visible when the parents
are sequenced.
evidence:
- reference: PMID:30739909
reference_title: "Variants in TCF20 in neurodevelopmental disability: description of 27 new patients and review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "we describe 27 patients, 26 of whom were identified via exome sequencing"
explanation: Exome sequencing as the ascertainment route for 26 of 27 patients.
- name: Chromosomal microarray for deletions and duplications
description: >-
Sequencing alone misses the copy-number half of the spectrum. Microarray
finds the whole-gene deletions and the reciprocal duplications, and both are
part of the TCF20-associated disease picture.
evidence:
- reference: PMID:30819258
reference_title: "De novo and inherited TCF20 pathogenic variants are associated with intellectual disability, dysmorphic features, hypotonia, and neurological impairments with similarities to Smith-Magenis syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Genome-wide analyses by exome sequencing (ES) and chromosomal microarray analysis (CMA) identified individuals with heterozygous, likely damaging, loss-of-function alleles in TCF20."
explanation: Names both assays as the ones that identified the patient set.
differential_diagnoses:
- name: Smith-Magenis syndrome
disease_term:
preferred_term: Smith-Magenis syndrome
term:
id: MONDO:0008434
label: Smith-Magenis syndrome
description: >-
The nearest clinical neighbour, and not by coincidence. RAI1, the
Smith-Magenis gene, is the structural relative of TCF20, and the two
proteins share the chromatin-binding architecture. The overlap is close
enough that the cohort paper defining TAND describes it in Smith-Magenis
terms.
evidence:
- reference: PMID:30819258
reference_title: "De novo and inherited TCF20 pathogenic variants are associated with intellectual disability, dysmorphic features, hypotonia, and neurological impairments with similarities to Smith-Magenis syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "TCF20 encodes a transcriptional co-regulator structurally related to RAI1, the dosage-sensitive gene responsible for Smith-Magenis syndrome (deletion/haploinsufficiency) and Potocki-Lupski syndrome (duplication/triplosensitivity)."
explanation: The paralogy that explains the clinical resemblance.
- reference: PMID:22081970
reference_title: "Identification of two independent nucleosome-binding domains in the transcriptional co-activator SPBP."
supports: SUPPORT
evidence_source: IN_VITRO
directness: INDIRECT
snippet: "RAI1 contains a region with homology to the novel nucleosome-binding region SPBP-(1551-1666) and an ePHD/ADD domain with ability to bind nucleosomes."
explanation: Shows the two proteins share the specific chromatin-binding domains, which grounds the paralogy at the molecular level. It is indirect because the work predates the TCF20 disease association.
- name: Rett syndrome and MECP2 duplication syndrome
disease_term:
preferred_term: Rett syndrome
term:
id: MONDO:0010726
label: Rett syndrome
description: >-
Reached through the shared chromatin complex rather than through shared gene
family. Rett-causing MECP2 mutations disrupt the MeCP2-TCF20 interaction, and
reducing Tcf20 partially rescued behavioural deficits caused by MECP2
overexpression, so the relationship is functional and bidirectional.
evidence:
- reference: PMID:35074918
reference_title: "Disruption of MeCP2-TCF20 complex underlies distinct neurodevelopmental disorders."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Importantly, RTT-causing mutations in MECP2 disrupt this interaction."
explanation: Places Rett syndrome mutations on the same complex as TCF20.
- reference: PMID:35074918
reference_title: "Disruption of MeCP2-TCF20 complex underlies distinct neurodevelopmental disorders."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "Reducing Tcf20 partially rescued the behavioral deficits caused by MECP2 overexpression, demonstrating a functional relationship between MeCP2 and TCF20 in MECP2 duplication syndrome pathogenesis."
explanation: A rescue experiment establishing that the two act on the same axis in opposite directions.
- name: TCF20 duplication neurodevelopmental disorder
description: >-
The reciprocal dosage disorder, with mirror traits. It shares the gene and
the locus, so a microarray finding of a 22q13.2 duplication rather than a
deletion points here instead.
evidence:
- reference: PMID:34904221
reference_title: "Rare and de novo duplications containing TCF20 are associated with a neurodevelopmental disorder."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "We propose that the TCF20 duplication could be involved in a new 22q13.2 microduplication syndrome with high penetrance, enlarging the genotype-phenotype knowledge of TCF20-associated NDDs."
explanation: The proposal of the reciprocal syndrome as a distinct entity.
- name: Phelan-McDermid syndrome
disease_term:
preferred_term: Phelan-McDermid syndrome
term:
id: MONDO:0011652
label: Phelan-McDermid syndrome
description: >-
The other 22q13 deletion disorder, and the one TAND was carved out of. A
terminal 22q13.3 deletion removing SHANK3 produces Phelan-McDermid
syndrome; the deletions that led to TCF20 sit proximal to it at 22q13.2 and
leave SHANK3 intact. The clinical pictures overlap, so a microarray finding
of a 22q13 deletion does not by itself distinguish them and the breakpoint
location does.
distinguishing_features:
- Sleep disturbance and movement disorders, proposed by the defining paper as
the features that clinically discriminate TCF20-associated disease
- SHANK3 involvement, the molecular discriminator, since the TCF20 deletions
sit proximal to the SHANK3 region and leave it intact
evidence:
- reference: PMID:30819258
reference_title: "De novo and inherited TCF20 pathogenic variants are associated with intellectual disability, dysmorphic features, hypotonia, and neurological impairments with similarities to Smith-Magenis syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "disorders associated with 22q13.2 deletions (encompassing TCF20) share similar features with Phelan –McDermid syndrome caused by deletion of SHANK3"
explanation: States the overlap that makes this a differential rather than an unrelated disorder.
- reference: PMID:30819258
reference_title: "De novo and inherited TCF20 pathogenic variants are associated with intellectual disability, dysmorphic features, hypotonia, and neurological impairments with similarities to Smith-Magenis syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Phenotypes specific for TCF20, such as sleep disturbances and movement disorders"
explanation: The authors' proposed clinical discriminators, which is what the distinguishing_features field records.
discussions:
- discussion_id: tand_dendritic_phenotype_translation
kind: HUMAN_MODEL_MISMATCH
prompt: >-
Does the dendritic and synaptic phenotype measured in TCF20-knockdown rodent
cortical cultures account for the human developmental and autistic
phenotype?
attaches_to:
- pathophysiology#Impaired Dendritic Arborization and Spine Formation
rationale: >-
The cellular mechanism is measured in rat cortical cultures under acute
knockdown, not in a heterozygous animal and not in human neurons. That is a
different genetic situation from the human disease, where one allele is lost
from conception and the other is intact. The direction of the synaptic
changes is also mixed rather than uniform, so the step from a reshaped
synaptic composition to intellectual disability and autism is an inference.
The entry types both edges out of this node as having unknown intermediates
for that reason.
evidence:
- reference: PMID:39801227
reference_title: "Regulation of Dendrite and Dendritic Spine Formation by TCF20."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "synaptosomal preparations of knockdown TCF20 rat cortical cultures showed significant downregulation of GluN2B and GABRA5, while GluA2 was significantly upregulated"
explanation: The mixed-direction result, in the knockdown system whose translational reach this gap questions.
- discussion_id: tand_craniofacial_dysmorphism_unconnected
kind: KNOWLEDGE_GAP
prompt: >-
By what route does TCF20 haploinsufficiency produce the craniofacial
features seen in two-thirds of patients?
attaches_to:
- phenotypes#Craniofacial Dysmorphism
rationale: >-
Every mechanism node in this entry is neuronal: the chromatin complex, the
neuronal transcriptional program, and dendritic and spine formation in
cortical culture. None of them reaches craniofacial development, so the
craniofacial phenotype is deliberately left with no incoming causal edge
rather than being attached to a neuronal node it does not follow from. The
gap is not that the finding is doubtful, it is reported in 18 of 27
patients, but that no cited work traces it to a mechanism. Its
unpatterned character makes this harder rather than easier, since there is
no recognizable gestalt to compare against a developmental field.
evidence:
- reference: PMID:30739909
reference_title: "Variants in TCF20 in neurodevelopmental disability: description of 27 new patients and review of literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "craniofacial features were reported in 18/27 (67%) and other minor malformations in 10/27 (37%), but did not appear to constitute a single recognizable or distinct phenotype"
explanation: >-
Establishes that the finding is common while stating that it has no
distinct pattern, which is the observation this gap is about.
- discussion_id: tand_germline_mosaicism_detection
kind: KNOWLEDGE_GAP
prompt: >-
How often is an apparently de novo TCF20 variant actually parental germline
mosaicism, and what tissue should be tested to find out?
attaches_to:
- genetic#TCF20
rationale: >-
Around 8% of reported cases are confirmed or suspected germline mosaicism,
but only two have physical confirmation, and in the documented family blood
testing of both parents was negative by Sanger and by deep sequencing. The
variant was found only by droplet digital PCR on urine-derived urothelial
cells. The true rate is therefore a lower bound set by what people happened
to test, and no protocol establishes which tissue to sample. This has direct
consequences for the recurrence risk quoted to a family.
evidence:
- reference: PMID:40011607
reference_title: "Germline mosaicism in TCF20-associated neurodevelopmental disorders: a case study and literature review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "discusses germline mosaicism as a likely under-detected mode of inheritance in neurodevelopmental conditions"
explanation: The authors state the under-detection directly, which is the uncertainty this gap records.
references:
- reference: PMID:30739909
title: "Variants in TCF20 in neurodevelopmental disability: description of 27 new patients and review of literature."
- reference: PMID:30819258
title: "De novo and inherited TCF20 pathogenic variants are associated with intellectual disability, dysmorphic features, hypotonia, and neurological impairments with similarities to Smith-Magenis syndrome."
- reference: PMID:35074918
title: "Disruption of MeCP2-TCF20 complex underlies distinct neurodevelopmental disorders."
- reference: PMID:39801227
title: "Regulation of Dendrite and Dendritic Spine Formation by TCF20."
- reference: PMID:40011607
title: "Germline mosaicism in TCF20-associated neurodevelopmental disorders: a case study and literature review."
- reference: PMID:34904221
title: "Rare and de novo duplications containing TCF20 are associated with a neurodevelopmental disorder."
- reference: PMID:22081970
title: "Identification of two independent nucleosome-binding domains in the transcriptional co-activator SPBP."
- reference: PMID:10995766
title: "The nuclear factor SPBP contains different functional domains and stimulates the activity of various transcriptional activators."
notes: >-
Deep-research provenance. Curated alongside an OpenScientist report
(research/TCF20-Associated_Neurodevelopmental_Disorder-deep-research-openscientist.md).
All 13 of its references resolved and all 16 quotes it checked were valid.
Its relevance heuristic is worth recording, because it was wrong in an
instructive way. Two references were flagged as off topic:
PMID:10995766 and PMID:22081970. Both are papers on SPBP, which is the former
symbol for TCF20, and both are directly on point: the first maps the protein's
functional domains and its coactivator behaviour, the second identifies its two
independent nucleosome-binding domains and shows that RAI1 carries homologous
domains. Neither mentions TCF20 or the disease anywhere, because both predate
the rename and the disease association. Relevance is scored on vocabulary
overlap with the report, so a paper about the same protein under a different
name scores as if it were about something else. Both are cited here, with
directness INDIRECT recording that they predate the disease association.
Ontology note. The report's term validation flagged one mislabelled term,
MONDO:0032745, as being called "MONDO" rather than by its label. That is the
identifier-table column header being read as a label, not a wrong binding.
Frequencies. The percentages curated here (69% autism, 67% attention or
hyperactivity, 24% structural brain anomalies, 12% seizures) all come from one
27-patient cohort compared against 17 previously reported patients, so they
are cohort figures rather than population frequencies, and the FrequencyEnum
bands assigned from them inherit that limitation.
Not curated. The report describes postnatal overgrowth (tall stature,
macrocephaly, obesity) in a subset. The 27-patient cohort cached here reports
the opposite: "In a majority of patients, we did not observe previously
reported findings of postnatal overgrowth or craniosynostosis, in comparison
with earlier reports." Those phenotypes are therefore omitted because the
strongest cached source argues against them in most patients, not merely
because no positive quote was found. The report's LOEUF figure (0.052) is
likewise uncurated: the cached source gives pLI = 1 and no LOEUF value, and a
constraint statistic taken from report prose alone would not be verifiable.
Craniofacial dysmorphism was omitted in the first version of this entry, on
the argument that "no recognizable facial gestalt" made a phenotype term
overclaim. That was wrong and was corrected in review. The absence of a
syndromic gestalt is not the absence of the finding, and HP:0001999 (Abnormal
facial shape) exists for exactly the under-specified case. It is now curated
at its 67% frequency, bound to the generic term, with the no-gestalt statement
quoted alongside so the limitation travels with the annotation instead of
being used to suppress it.
Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.
Record notes
Deep-research provenance. Curated alongside an OpenScientist report (research/TCF20-Associated_Neurodevelopmental_Disorder-deep-research-openscientist.md). All 13 of its references resolved and all 16 quotes it checked were valid. Its relevance heuristic is worth recording, because it was wrong in an instructive way. Two references were flagged as off topic: PMID:10995766 and PMID:22081970. Both are papers on SPBP, which is the former symbol for TCF20, and both are directly on point: the first maps the protein's functional domains and its coactivator behaviour, the second identifies its two independent nucleosome-binding domains and shows that RAI1 carries homologous domains. Neither mentions TCF20 or the disease anywhere, because both predate the rename and the disease association. Relevance is scored on vocabulary overlap with the report, so a paper about the same protein under a different name scores as if it were about something else. Both are cited here, with directness INDIRECT recording that they predate the disease association. Ontology note. The report's term validation flagged one mislabelled term, MONDO:0032745, as being called "MONDO" rather than by its label. That is the identifier-table column header being read as a label, not a wrong binding. Frequencies. The percentages curated here (69% autism, 67% attention or hyperactivity, 24% structural brain anomalies, 12% seizures) all come from one 27-patient cohort compared against 17 previously reported patients, so they are cohort figures rather than population frequencies, and the FrequencyEnum bands assigned from them inherit that limitation. Not curated. The report describes postnatal overgrowth (tall stature, macrocephaly, obesity) in a subset. The 27-patient cohort cached here reports the opposite: "In a majority of patients, we did not observe previously reported findings of postnatal overgrowth or craniosynostosis, in comparison with earlier reports." Those phenotypes are therefore omitted because the strongest cached source argues against them in most patients, not merely because no positive quote was found. The report's LOEUF figure (0.052) is likewise uncurated: the cached source gives pLI = 1 and no LOEUF value, and a constraint statistic taken from report prose alone would not be verifiable. Craniofacial dysmorphism was omitted in the first version of this entry, on the argument that "no recognizable facial gestalt" made a phenotype term overclaim. That was wrong and was corrected in review. The absence of a syndromic gestalt is not the absence of the finding, and HP:0001999 (Abnormal facial shape) exists for exactly the under-specified case. It is now curated at its 67% frequency, bound to the generic term, with the no-gestalt statement quoted alongside so the limitation travels with the annotation instead of being used to suppress it.
Create: TCF20-Associated Neurodevelopmental Disorder (TAND / DDVIBA) · 2026-09-05T15:11:58Z · View source
New kb/disorders entry for TAND (MONDO:0032745), claimed via issue #11109. Curated as a dosage disorder of a chromatin complex rather than as a syndrome description: TCF20 haploinsufficiency reduces occupancy of the MeCP2-PHF14-TCF20 complex, dysregulating the neuronal transcriptional program and impairing dendritic arborization and spine formation. The differential is built on that mechanism, since Smith-Magenis (RAI1 paralogy, shared nucleosome-binding domains), Rett and MECP2 duplication syndrome (same complex, with a Tcf20-reduction rescue of MECP2-overexpression behavioural deficits) and the reciprocal TCF20 duplication disorder all connect through it rather than through shared phenotype lists. Ten HPO-bound phenotypes with cohort frequencies from Torti 2019, four treatments, two KNOWLEDGE_GAP/HUMAN_MODEL_MISMATCH discussions. Deep research: OpenScientist report committed; 13/13 references resolved and 16/16 checked quotes valid. Its relevance heuristic flagged PMID:10995766 and PMID:22081970 as off topic; both are SPBP papers, SPBP being the former symbol for TCF20, and both are directly on point. They are cited here with directness INDIRECT recording that they predate the disease association. This is a vocabulary-overlap failure of relevance scoring rather than a citation problem, and is worth knowing about for any gene with a former symbol. One snippet from PMID:22081970 had to be requoted around a bracketed abbreviation expansion that the reference validator strips (issue #10192). Deliberately not curated: postnatal overgrowth and craniofacial dysmorphism, the first because no cached source carries a quotable statement of it and the second because the same source states there is no recognizable facial gestalt, so a phenotype term would assert more structure than the finding has. Validation: schema pass, term validation pass, 43/43 snippets verified, check-entity-refs / check-causal-targets / check-duplicate-keys / check-enum-values clean.
Disease: TCF20-Associated Neurodevelopmental Disorder (TAND) Also known as: Developmental Delay with Variable Intellectual Impairment and Behavioral Abnormalities (DDVIBA) MONDO: MONDO:0032745 · OMIM: #618430 · Gene: TCF20 (HGNC:11631), 22q13.2 Category: Mendelian, autosomal dominant Report basis: Aggregated disease-level literature and ontology/database resources (no patient-level EHR data). Evidence drawn from human clinical cohorts, in vitro/biochemical studies, and mouse/cellular models, as indicated per claim.
TCF20-associated neurodevelopmental disorder (TAND), catalogued in OMIM as "Developmental delay with variable intellectual impairment and behavioral abnormalities" (DDVIBA, #618430), is a rare autosomal-dominant neurodevelopmental disorder caused by loss-of-function/haploinsufficiency of TCF20, a dosage-sensitive chromatin-binding transcriptional co-regulator on chromosome 22q13.2. TCF20 (also called SPBP) is structurally and functionally related to RAI1, the gene responsible for Smith–Magenis syndrome, and the two disorders share substantial clinical overlap. The core phenotype — fully penetrant developmental delay/intellectual disability plus hypotonia — is accompanied in a majority of patients by autism spectrum features (~69%), attention/hyperactivity problems (~67%), and non-specific craniofacial dysmorphism (~67%), with variable movement disorders, sleep disturbance, seizures (~12%), structural brain anomalies (~24%), and, in a subset, postnatal overgrowth (tall stature, macrocephaly, obesity).
Mechanistically, TCF20 acts within a neuronal MeCP2–PHF14–TCF20 chromatin complex that co-regulates key neuronal genes. Reduced TCF20 dosage dysregulates this transcriptional program, and reciprocal dosage changes produce "mirror" phenotypes: deletions/loss-of-function cause TAND, whereas duplications spanning TCF20 cause a related 22q13.2 microduplication neurodevelopmental disorder. The gene is extremely intolerant to loss of function in gnomAD (pLI = 1.0, LOEUF = 0.052), and its pathogenic variant spectrum is overwhelmingly truncating (frameshift, nonsense, splice) or whole-gene deletion, exactly as predicted for a haploinsufficiency mechanism.
The disorder is diagnosed molecularly (predominantly by trio exome sequencing, with chromosomal microarray detecting deletions/duplications). Most cases are de novo (~67%), a minority are inherited from mildly affected parents (~10%), and a notable ~8% arise via germline mosaicism, which has direct genetic-counseling implications for recurrence risk. There is no disease-specific or targeted therapy; management is entirely supportive (early intervention, physical/occupational/speech therapy, behavioral and pharmacologic management of ASD/ADHD, antiseizure medication, sleep/melatonin support). The course is chronic, lifelong, and non-degenerative, with reported patients ranging from 2 to 68 years of age.
Overview. TAND is a Mendelian neurodevelopmental disorder defined by heterozygous inactivation of TCF20. First delineated as a discrete syndrome in 2019 through two large concurrent cohort studies (PMID: 30819258; PMID: 30739909), it had earlier been implicated in autism spectrum disorder (PMID: 25228304) and in an intellectual-disability–overgrowth phenotype (PMID: 27436265). Vetrini et al. established that "TCF20 pathogenic variants are associated with a novel syndrome manifesting clinical characteristics similar to those observed in Smith-Magenis syndrome."
Key identifiers.
| Resource | Identifier |
|---|---|
| MONDO | MONDO:0032745 |
| OMIM (phenotype) | #618430 (DDVIBA) |
| OMIM (gene) | 603107 (TCF20) |
| UMLS | C5193092 |
| MedGen | 1676192 |
| GARD | 0018517 |
| HGNC | 11631 |
| Entrez Gene | 6942 |
| Ensembl | ENSG00000100207 |
| ICD-10 / ICD-11 | No specific code; subsumed under ICD-10 F79/F88 or ICD-11 6A00 (disorders of intellectual development) |
| Orphanet | No dedicated ORPHA number identified |
Synonyms / alternative names. DDVIBA; TCF20-related disorder; TCF20-related syndrome; TCF20-associated neurodevelopmental disorder (TAND). The gene TCF20 carries aliases SPBP, AR1, TCF-20, and DDVIBA.
Information source. Evidence is derived from aggregated disease-level resources (OMIM, ClinVar, gnomAD, HPO) and from published individual-patient case series/cohorts (Torti 2019, Vetrini 2019, Poquérusse 2025), not from a single EHR system.
Primary cause — genetic. TAND is a monogenic disorder caused by heterozygous loss-of-function of TCF20. Vetrini et al. reported "25 unique inactivating single nucleotide variants/indels (1 missense, 1 canonical splice-site variant, 18 frameshift, and 5 nonsense) and 4 deletions of TCF20" (PMID: 30819258). The reciprocal dosage change — duplication spanning TCF20 — causes a related disorder: "Duplication including TCF20 was suspected to cause a neurodevelopmental disorder (NDD) with mirror traits compared to patients with TCF20 deletions" (PMID: 34904221).
Genetic risk factors. The causal variant is the disease. No independent susceptibility loci or modifier genes are established. Because TCF20 lies within 22q13, larger 22q13 deletions (Phelan–McDermid spectrum) can co-delete TCF20 alongside SHANK3 and contribute to phenotype severity (PMID: 30216695; PMID: 42192297).
Environmental risk factors. None established. As a fully penetrant Mendelian dominant disorder for developmental delay/ID, no environmental exposures, lifestyle factors, or infectious agents are implicated in causation.
Protective factors. None identified. No protective alleles or modifier variants are described.
Gene–environment interactions. None documented. There is no evidence for GxE modulation of this monogenic phenotype.
TAND phenotypes span neurological, behavioral, musculoskeletal, growth, craniofacial, ophthalmologic, and gastrointestinal domains. The full HPO catalog for OMIM:618430 comprises ~50 terms. Cohort-level frequencies derive principally from Torti et al. (PMID: 30739909): "All had developmental delay/intellectual disability. Autism spectrum disorders/autistic features were reported in 69%, attention disorders or hyperactivity in 67%, craniofacial features (no recognizable facial gestalt) in 67%, structural brain anomalies in 24%, and seizures in 12%."
| Phenotype | HPO term | Frequency | Type | Onset |
|---|---|---|---|---|
| Global developmental delay | HP:0001263 | 100% | Clinical sign | Infantile |
| Intellectual disability (typically mild) | HP:0001256 | 100% (fully penetrant) | Clinical sign | Childhood |
| Motor delay | HP:0001270 | Common | Clinical sign | Infantile |
| Delayed speech/language | HP:0000750 | Common | Clinical sign | Early childhood |
| Autistic behavior / ASD | HP:0000729 | ~69% | Behavioral | Early childhood |
| Hyperactivity / ADHD | HP:0000752 | ~67% | Behavioral | Childhood |
| Anxiety | HP:0000739 | Variable | Behavioral | Childhood |
| Aggressive behavior | HP:0000718 | Variable | Behavioral | Childhood |
| Compulsive / stereotypic behavior | HP:0000722 / HP:0000733 | Variable | Behavioral | Childhood |
| Seizure | HP:0001250 | ~12% | Clinical sign | Variable |
| Ataxia / incoordination | HP:0001251 / HP:0002311 | Subset | Clinical sign | Variable |
| Sleep disturbance | HP:0002360 | Frequent | Clinical sign | Childhood |
Severity/progression. Intellectual disability is generally mild and, critically, stable and non-regressive — distinguishing TAND from Rett syndrome despite the shared MeCP2 axis. Expressivity is variable; DD/ID is fully penetrant while ASD is incompletely penetrant.
Quality-of-life impact. No disease-specific EQ-5D/SF-36/PROMIS data exist. QoL impact is inferred from the burden of lifelong ID, ASD, ADHD, sleep disturbance, and movement problems, which collectively affect education, independent living, communication, and family functioning.
Causal gene. TCF20 (HGNC:11631; Entrez 6942; Ensembl ENSG00000100207; OMIM gene 603107), located at chr22q13.2 (GRCh38 chr22:42,160,013–42,343,616, minus strand). Aliases: SPBP, AR1, TCF-20, DDVIBA.
Pathogenic variant landscape. ClinVar (queried 2026-09) lists ~1,377 submitted variants for TCF20: 316 Pathogenic, 44 Likely pathogenic (~360 P/LP), and 1,234 VUS. The pathogenic set is dominated by truncating (frameshift/nonsense/splice) and deletion alleles, consistent with haploinsufficiency; the large VUS fraction reflects abundant tolerated missense variation. This mirrors the cohort spectrum of "1 missense, 1 canonical splice-site variant, 18 frameshift, and 5 nonsense... and 4 deletions" (PMID: 30819258).
Variant classification. Per ACMG/AMP, truncating variants in a haploinsufficient gene meet strong LoF criteria (PVS1); recurrent LoF variants in unrelated families and de novo occurrence add supporting evidence. Missense variants are largely VUS given the lack of missense constraint.
Allele frequency / constraint (gnomAD, GRCh38).
| Metric | Value | Interpretation |
|---|---|---|
| pLI | 1.0 | Extreme LoF intolerance |
| LOEUF (oe_lof upper) | 0.052 | Highly constrained |
| observed/expected LoF | 0.020 (3 obs vs 148.6 exp) | Near-complete LoF depletion |
| LoF Z | 10.13 | Strongly constrained |
| Missense Z | 0.69 | Not missense-constrained |
Somatic vs germline. Germline. Pathogenic variants are constitutional; a notable fraction arise via germline (gonadal) mosaicism in a transmitting parent (see Section 9).
Functional consequence. Loss of function / haploinsufficiency. Reduced TCF20 dosage is the disease driver; the reciprocal duplication produces a "mirror" gain-of-dosage phenotype (PMID: 34904221).
Modifier genes. None specifically validated for TCF20. In the 22q13 deletion context, co-deleted neighboring genes (e.g., SHANK3, CELSR1, and others) modify the composite phenotype (PMID: 42192297).
Epigenetic information. TCF20 itself is a chromatin-associated transcriptional co-regulator (see Section 6); no disease-specific DNA-methylation episignature has been formally validated in the reviewed literature, though its mechanistic partner MeCP2 is a methyl-CpG reader, placing TAND within the broader chromatinopathy/methylation-reader disease space.
Chromosomal abnormalities. Whole-gene and contiguous 22q13.2 deletions cause TAND; 22q13.2 microduplications spanning TCF20 cause the reciprocal disorder. A pericentric chromosome 22 inversion physically disrupting TCF20 was the original ASD-linked lesion (PMID: 25228304).
Not applicable. TAND is a monogenic disorder with no established environmental, lifestyle, or infectious contributors to causation. Environmental factors are relevant only as general supportive-care considerations (e.g., seizure precautions, developmental stimulation), not as etiologic agents.
Branch — gain-of-dosage: Increased TCF20 dosage (22q13.2 microduplication) results in a reciprocal "mirror" neurodevelopmental disorder (PMID: 34904221), underscoring bidirectional dosage sensitivity.
TCF20/SPBP protein. A nuclear multidomain transcriptional co-activator: N-terminal transactivation region, an AT-hook DNA-binding domain, a bipartite nuclear localization signal, and a C-terminal extended PHD (ePHD/ADD) zinc-finger domain of the trithorax family. Rekdal et al. defined it as "a nuclear, multidomain protein containing an N-terminal region with transactivating ability, a novel type of DNA-binding domain containing an AT hook motif, and a bipartite nuclear localization signal as well as a C-terminal zinc finger domain" (PMID: 10995766). It enhances transactivation by c-Jun, Ets1, Sp1, Pax6, and the androgen receptor (PMID: 21935435).
Chromatin engagement. TCF20/SPBP has two independent nucleosome-binding domains and, like its homolog RAI1, is "strongly enriched on chromatin in interphase HeLa cells, and both proteins display low nuclear mobility" (PMID: 22081970) — behavior typical of a chromatin scaffolding co-regulator.
The MeCP2 axis. Zhou et al. used proximity-dependent biotinylation (BioID) to identify "a transcription factor 20 (TCF20) complex that interacts with MeCP2 at the chromatin interface. Importantly, RTT-causing mutations in MECP2 disrupt this interaction. TCF20 and MeCP2 are highly coexpressed in neurons and coregulate the expression of key neuronal genes" (PMID: 35074918). They further showed dosage sensitivity in vivo: "Reducing Tcf20 partially rescued the behavioral deficits caused by MECP2 overexpression, demonstrating a functional relationship between MeCP2 and TCF20 in MECP2 duplication syndrome pathogenesis," and identified "a patient exhibiting RTT-like neurological features with a missense mutation in the PHF14 subunit of the TCF20 complex that abolishes the MeCP2-PHF14-TCF20 interaction." This places TAND firmly within the MeCP2/Rett-spectrum chromatinopathy family.
Cellular processes / cell types. Pathology is transcriptional dysregulation in neurons (CL:0000540), including forebrain glutamatergic (CL:0000679) and GABAergic (CL:0000617) neurons where TCF20 and MeCP2 are highly coexpressed. Core biological processes: regulation of transcription, DNA-templated (GO:0006355) and chromatin binding (GO:0003682).
Subcellular localization. Nucleus (GO:0005634), chromatin (GO:0000785), chromosome (GO:0005694).
TCF20 LoF variant (frameshift/nonsense/splice/deletion)
│ haploinsufficiency (pLI=1.0)
▼
↓ TCF20 protein dosage
│
▼
Impaired MeCP2–PHF14–TCF20 chromatin complex ◄── PHF14 missense (RTT-like)
│ (BioID-validated; MECP2 mutations also disrupt)
▼
Dysregulated transcription of neuronal target genes
│
▼
Abnormal neuronal maturation / circuit function (inferred)
│
▼
DD/ID · ASD · ADHD · hypotonia · movement disorder · sleep disturbance · seizures
[MIRROR BRANCH] 22q13.2 duplication → ↑TCF20 dosage → reciprocal NDD
There is no evidence for metabolic, immune, oxidative-stress, ischemic, fibrotic, or enzyme-deficiency mechanisms; TAND is a transcriptional/chromatin regulatory disorder.
Organ / system level. The central nervous system (UBERON:0000955 brain; UBERON:0001017 CNS; UBERON:0001016 nervous system) is the primary affected organ. Regions implicated by clinical features include the cerebral cortex (UBERON:0000956) and forebrain (cognition, speech, motor control), the cerebellum (UBERON:0002037; inferred from ataxia/incoordination), and basal ganglia (inferred from dystonia/movement disorder). Structural brain MRI anomalies are non-specific and present in ~24% of patients, bilateral with no consistent lateralization.
Secondary systems. Musculoskeletal (hypotonia; muscle UBERON:0002385; scoliosis), craniofacial skeleton (dysmorphism), eye (UBERON:0000970; strabismus/myopia), gastrointestinal (constipation, feeding difficulty), and endocrine/growth axis (overgrowth subset).
Tissue and cell level. Nervous tissue; neurons (CL:0000540), with forebrain glutamatergic (CL:0000679) and GABAergic (CL:0000617) subtypes highlighted by TCF20/MeCP2 coexpression.
Subcellular level. Nucleus (GO:0005634), chromatin (GO:0000785), chromosome (GO:0005694).
Lateralization. Bilateral/symmetric where CNS structural changes occur; no systematic lateralization reported.
Onset. Congenital/infantile (Infantile onset, HP:0003593). Developmental delay is typically recognized in infancy or early childhood; hypotonia may be noted neonatally.
Progression. The disorder is chronic, stable, and non-degenerative. There is no evidence of regression (contrasting with classic Rett syndrome). Torti et al. ascertained patients "ranged in age from 2 to 68 years" (PMID: 30739909), supporting a lifelong but non-progressive course with normal or near-normal survival.
Disease course pattern. Static encephalopathy pattern; intellectual disability persists but does not worsen neurodegeneratively. Seizures and behavioral features may fluctuate and require ongoing management.
Critical periods. Early childhood is the key window for developmental intervention (early intervention, therapies); no biological disease-modifying window is defined given the absence of targeted therapy.
Remission. None; the underlying genetic lesion is constitutional and permanent. Symptomatic domains (e.g., seizures, sleep, behavior) can be managed/controlled but not cured.
Inheritance pattern. Autosomal dominant (HP:0000006).
De novo vs inherited vs mosaic. Across ~91 reported individuals (Poquérusse 2025 review): "~67% of cases arose de novo, while ~10% were inherited, and, intriguingly, ~8% were either confirmed or suspected to have arisen via germline mosaicism" (PMID: 40011607). Vetrini et al. found variants "de novo in 20 instances and inherited from 4 symptomatic parents in 5 [families], including in one set of monozygotic twins" (PMID: 30819258).
Germline mosaicism. Physically demonstrated: in one family, "droplet digital PCR (ddPCR) of DNA derived from early morning urine detected the variation in 3.2% of the father's urothelial cells, confirming germline mosaicism" (PMID: 40011607). This substantially informs recurrence-risk counseling: parents of a "de novo" proband may carry undetectable-in-blood gonadal mosaicism, elevating sibling recurrence risk above the population baseline.
Penetrance / expressivity. DD/ID is fully penetrant; ASD and other features show incomplete penetrance and variable expressivity, including mildly affected transmitting parents.
Constraint / carrier frequency. TCF20 is extremely LoF-intolerant (pLI = 1.0), so pathogenic LoF alleles are essentially absent from the general (gnomAD) population; there is no meaningful "carrier" population for a dominant, highly penetrant condition.
Genetic anticipation / founder effects / consanguinity. Not applicable (no repeat-expansion mechanism; no reported founder alleles; dominant mechanism unrelated to consanguinity).
Epidemiology. Prevalence and incidence are not formally established; TAND is a rare disorder with ~91 reported individuals to date. It is likely underdiagnosed and increasingly recognized as exome sequencing becomes routine in NDD workups.
Demographics. No strong ethnic predilection reported; two recurrent LoF variants were observed in unrelated families (PMID: 30819258). Sex ratio is not established as strongly skewed for the core NDD phenotype (autosomal gene). Age distribution of ascertained patients spans 2–68 years.
Diagnostic approach. Diagnosis is molecular. The principal modality is trio exome sequencing (ES); Torti et al. identified patients "26 of whom were identified via exome sequencing" (PMID: 30739909), and Vetrini et al. noted "Genome-wide analyses by exome sequencing (ES) and chromosomal microarray analysis (CMA) identified individuals with heterozygous, likely damaging, loss-of-function alleles in TCF20" (PMID: 30819258).
| Test | Utility in TAND |
|---|---|
| Whole exome sequencing (WES) | Primary diagnostic yield; detects SNVs/indels |
| Whole genome sequencing (WGS) | Useful for non-coding/structural variants missed by ES |
| Chromosomal microarray (CMA) | Detects 22q13.2 deletions and duplications |
| Multigene NDD/epilepsy/ID panels | TCF20 included in modern ID/ASD panels |
| Single-gene testing | For cascade testing of a known familial variant |
| Karyotype/FISH | Historically detected large rearrangements (e.g., chr22 inversion, PMID: 25228304) |
| ddPCR (urine/other tissue) | Confirms parental germline mosaicism (PMID: 40011607) |
Biomarkers / labs. There is no specific biochemical biomarker, metabolite, or enzyme assay. No metabolomic/proteomic diagnostic signature is validated.
Imaging / electrophysiology. Brain MRI shows non-specific structural anomalies in ~24% (Torti 2019). EEG is used for seizure evaluation (~12% have seizures).
Clinical criteria. No formal DSM/ICD diagnostic criteria specific to TAND; diagnosis rests on identification of a pathogenic TCF20 variant in a compatible clinical context.
Differential diagnosis.
| Condition | Gene/locus | Distinguishing features |
|---|---|---|
| Smith–Magenis syndrome | RAI1 | Closest mimic; RAI1 is TCF20's paralog; overlapping behavior/sleep phenotype (PMID: 30819258) |
| Phelan–McDermid syndrome | 22q13.3 / SHANK3 | Overlapping 22q13 deletions; TCF20 co-deletion in larger deletions (PMID: 30216695, PMID: 42192297) |
| Rett / MECP2-related disorders | MECP2 | Shared MeCP2 axis; but TAND is non-regressive |
| Other overgrowth-ID syndromes | e.g., NSD1, EZH2 | Overlap in overgrowth subset (PMID: 27436265) |
Upadia et al. noted that in 22q13.2 microdeletions encompassing TCF20, "All eight patients share features common to patients with PMS including developmental delay and language delay" (PMID: 30216695), reinforcing the Phelan–McDermid overlap.
Screening. No newborn or population carrier screening exists. Cascade testing of at-risk relatives follows identification of a familial variant.
Survival / mortality. TAND is not a life-limiting disorder in the way of neurodegenerative conditions; the reported age range (2–68 years) indicates normal or near-normal survival into adulthood (PMID: 30739909). No disease-specific mortality rate is established.
Morbidity / function. The principal burden is lifelong intellectual disability (usually mild), plus ASD, ADHD, hypotonia, sleep disturbance, and — in subsets — seizures, movement disorders, and behavioral challenges. These cause meaningful disability in learning, communication, adaptive functioning, and independent living.
Disease course. Chronic, stable, non-degenerative. Complications are those of the associated features (e.g., seizure-related, orthopedic from hypotonia/scoliosis, feeding/constipation, behavioral).
Recovery potential. No recovery of the underlying deficit; developmental gains occur with intervention but ID persists.
Prognostic factors. Severity correlates loosely with variant type/deletion size in contiguous-gene contexts (larger 22q13 deletions co-deleting additional genes tend to be more severe, PMID: 42192297). No validated molecular prognostic biomarker exists.
QoL measures. No disease-specific validated instruments; generic pediatric/NDD QoL tools apply.
No disease-specific or FDA-approved targeted therapy, gene therapy, RNA therapy, or clinical trial exists for TCF20 to date. Management is entirely supportive and symptom-directed (NCIT: Supportive Care Intervention).
| Domain | Intervention | NCIT-type category |
|---|---|---|
| Developmental delay / ID | Early intervention, special education | Rehabilitation therapy |
| Motor delay / hypotonia | Physical & occupational therapy | Physical therapy |
| Speech/language delay | Speech-language therapy | Speech therapy |
| ASD | Behavioral therapy (ABA), structured supports | Behavioral intervention |
| ADHD/hyperactivity | Stimulants / non-stimulant pharmacotherapy | Pharmacotherapy |
| Seizures | Antiseizure medications | Anticonvulsant therapy |
| Sleep disturbance | Sleep hygiene, melatonin | Supportive care |
| Movement disorder/dystonia | Symptom-directed pharmacologic/PT management | Supportive care |
| Constipation/feeding | Nutritional and GI management | Supportive care |
| Scoliosis | Orthopedic monitoring/management | Surgical/interventional |
Pharmacogenomics. No TCF20-specific pharmacogenomic guidance; standard PGx applies to any prescribed psychotropics/antiseizure agents.
Advanced/experimental therapeutics. None; the MeCP2–TCF20 dosage biology suggests dosage-restoration strategies are theoretically attractive but none are in development.
Treatment strategy. Multidisciplinary care coordinated through developmental pediatrics/clinical genetics, with individualized therapy plans and genetic counseling for the family.
Primary prevention. Not applicable for the disorder itself (a constitutional genetic condition). Genetic counseling is the principal preventive tool: for de novo cases, sibling recurrence risk is low but non-negligible because of documented germline mosaicism (~8% of cases; PMID: 40011607); for inherited cases, the transmitting parent has a 50% transmission risk.
Reproductive options. Prenatal diagnosis and preimplantation genetic testing (PGT) are available when a familial pathogenic variant is known.
Secondary prevention. Early molecular diagnosis (via ES/CMA in NDD workup) enables early intervention and anticipatory management of seizures, sleep, and behavior.
Tertiary prevention. Prevent complications through seizure control, orthopedic surveillance (scoliosis), management of sleep and behavior, and educational support.
Immunization / public health / prophylaxis. Not applicable — no infectious or environmental etiology.
Orthologs.
| Species | Gene | Identifier |
|---|---|---|
| Mouse (Mus musculus, NCBI Taxon 10090) | Tcf20 | MGI:108399; Entrez 21411; ENSMUSG00000041852 |
| Rat (Rattus norvegicus, Taxon 10116) | Tcf20 | Entrez 366964 |
| Zebrafish (Danio rerio, Taxon 7955) | tcf20 | Entrez 100006417 |
Natural disease in other species. No naturally occurring TCF20-associated disease is catalogued in companion animals or wildlife (no OMIA entry identified). The gene is evolutionarily conserved, and its paralog RAI1 underlies conserved dosage-sensitive behavioral biology, supporting cross-species conservation of the underlying mechanism.
Zoonotic potential / transmission. Not applicable (non-infectious genetic disorder).
Mouse (mammalian in vivo). The most informative model. Zhou et al. showed Tcf20 and Mecp2 are highly coexpressed in neurons and co-regulate neuronal genes; genetically reducing Tcf20 partially rescued behavioral deficits caused by MECP2 overexpression, establishing a dosage-sensitive Tcf20–MeCP2 functional relationship in vivo (PMID: 35074918). This model recapitulates the dosage-sensitivity axis central to TAND pathophysiology (and to the mirror duplication phenotype), though a dedicated Tcf20 haploinsufficiency mouse fully phenocopying the human syndrome is not comprehensively characterized in the reviewed literature — a notable gap.
Cellular models. Tcf20 was identified in a mammalian RNAi screen as a modifier of mutant huntingtin aggregation: "As for Tcf20, which contains polyQ stretches at N-terminus, its binding to mutant huntingtin aggregates is observed in neuro2a cells and in HD model mouse neurons" (PMID: 24705917) — indicating a polyQ-containing protein with neuronal aggregation-associated behavior.
In vitro biochemistry. SPBP/TCF20 chromatin-binding and coactivator assays in HeLa and reporter systems defined its domain architecture, nucleosome-binding domains, and coactivator partnerships (PMID: 10995766; PMID: 22081970; PMID: 21935435).
Model resources. MGI (mouse), RGD (rat), ZFIN (zebrafish). No iPSC/organoid TAND models were identified in the reviewed literature.
Recapitulation / limitations. Existing models validate the molecular dosage mechanism (TCF20–MeCP2 co-regulation) rather than the full behavioral/craniofacial/growth syndrome. Limitations include incomplete behavioral phenotyping of Tcf20-haploinsufficient animals and absence of patient-derived neuronal models.
TAND is best understood as a dosage-sensitive chromatinopathy. TCF20/SPBP is a chromatin-tethered transcriptional co-regulator that, together with MeCP2 (the Rett-syndrome protein) and PHF14, forms a complex that co-regulates neuronal gene programs. The disorder sits at the intersection of two well-known dosage-sensitive paradigms:
RAI1 paralogy → Smith–Magenis / Potocki–Lupski analogy. Just as RAI1 deletion causes Smith–Magenis and duplication causes Potocki–Lupski, TCF20 loss causes TAND and duplication causes a reciprocal "mirror" NDD. The structural/functional relatedness of TCF20 and RAI1 — "TCF20 encodes a transcriptional co-regulator structurally related to RAI1, the dosage-sensitive gene responsible for Smith-Magenis syndrome (deletion/haploinsufficiency) and Potocki-Lupski syndrome (duplication/triplosensitivity)" (PMID: 30819258) — explains the striking clinical overlap with Smith–Magenis (behavioral phenotype, sleep disturbance).
MeCP2 partnership → Rett-spectrum linkage. Because TCF20 physically and functionally cooperates with MeCP2, TCF20 disruption produces overlapping neuronal transcriptional dysregulation — but, importantly, without the regressive course of classic Rett syndrome, likely reflecting the distinct target-gene consequences of losing a partner co-regulator versus losing the methyl-CpG reader itself.
The convergence of extreme gnomAD LoF constraint (pLI = 1.0), a truncating-dominant ClinVar/cohort variant spectrum, a validated dosage-sensitive in vivo genetic interaction, and a reciprocal duplication phenotype forms an unusually coherent, mutually reinforcing evidence base for haploinsufficiency as the mechanism.
| Paper | PMID | Contribution |
|---|---|---|
| Vetrini et al. 2019 — De novo and inherited TCF20 pathogenic variants... | 30819258 | Delineated the syndrome; variant spectrum (LoF-dominant); Smith–Magenis similarity; ES+CMA diagnostics; de novo/inherited breakdown |
| Torti et al. 2019 — Variants in TCF20 in neurodevelopmental disability | 30739909 | Largest cohort; phenotype frequencies (DD/ID 100%, ASD 69%, ADHD 67%, craniofacial 67%, brain anomalies 24%, seizures 12%); age range 2–68 |
| Zhou et al. 2022 — Disruption of MeCP2-TCF20 complex... | 35074918 | Core mechanism: BioID-defined MeCP2–PHF14–TCF20 complex; dosage rescue in mouse; PHF14 patient |
| Lévy et al. 2022 — Rare and de novo duplications containing TCF20... | 34904221 | Reciprocal duplication "mirror" phenotype; expanded neurological feature set |
| Schäfgen et al. 2016 — De novo nonsense/frameshift... postnatal overgrowth | 27436265 | Overgrowth subphenotype; incomplete ASD penetrance |
| Babbs et al. 2014 — TCF20/SPBP in autism spectrum disorder | 25228304 | First ASD linkage; chr22 inversion; germinal mosaicism; RAI1 relatedness |
| Poquérusse et al. 2025 — Germline mosaicism in TAND | 40011607 | Case counts (~91); inheritance breakdown; ddPCR-confirmed germline mosaicism |
| Upadia et al. 2018 — 22q13.2 microdeletion encompassing TCF20/TNFRSF13C | 30216695 | Contiguous-gene/differential-diagnosis context (Phelan–McDermid overlap) |
| Ricciardello et al. — 22q13 terminal deletion size and clinical features | 42192297 | Deletion-size/phenotype correlation; neighboring-gene modifiers (incl. TCF20) |
| Rekdal et al. 2000 — Nuclear factor SPBP domains | 10995766 | Protein domain architecture / coactivator function |
| Darvekar et al. 2012 — Two nucleosome-binding domains in SPBP | 22081970 | Chromatin-binding behavior shared with RAI1 |
| Corsi et al. 2011 — Pax6 represses AR via SPBP | 21935435 | Coactivator partnerships (AR, Pax6) |
| Yamanaka et al. 2014 — RNAi screen, huntingtin aggregation | 24705917 | Cellular model; Tcf20 polyQ / aggregation biology |
Report compiled from OMIM, ClinVar, gnomAD, HGNC/Ensembl, HPO (OMIM:618430), and primary literature. Evidence source types are indicated throughout: human clinical cohorts (Torti, Vetrini, Schäfgen, Poquérusse, Lévy, Upadia), model organism (Zhou mouse; Yamanaka cellular), and in vitro biochemistry (Rekdal, Darvekar, Corsi).
Checked with linkml-reference-validator 0.2.1.
| Outcome | Count |
|---|---|
| References checked | 13 |
| Resolved | 13 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| Quoted claims checked | 16 |
| Quoted claims found in source | 16 |
| Quoted claims not found in source | 0 |
| References weighed for topical relevance | 13 |
| On topic | 9 |
| Off topic | 2 |
These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:
PMID:10995766 (6 mentions) - The nuclear factor SPBP contains different functional domains and stimulates the activity of various transcriptional activators.PMID:22081970 (6 mentions) - Identification of two independent nucleosome-binding domains in the transcriptional co-activator SPBP.Weighed against this report's own most characteristic terms: tcf20, disorder, tand, phenotype, gene, behavioral, mecp2, variant, clinical, developmental, seizure, syndrome, sleep, deletion, duplication, delay, asd, feature, patient, mechanism.
All extracted references resolved successfully. Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.
Checked with linkml-term-validator 0.4.5, through the ols: adapter.
| Outcome | Count |
|---|---|
| Terms checked | 67 |
| Resolved | 64 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 0 |
| Unverifiable | 3 |
| Terms whose name was checked | 20 |
| Terms named correctly | 10 |
| Terms named as a different term | 1 |
| Terms whose name is worth a second look | 9 |
These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:
MONDO:0032745 (2 mentions) - the report calls it "MONDO"; MONDO calls it developmental delay with variable intellectual impairment and behavioral abnormalitiesThe report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:
HP:0001256 (1 mention) - the report calls it "Intellectual disability (typically mild)"; HP calls it Mild intellectual disability, and lists "Intellectual disability, mild" among its other namesHP:0000750 (1 mention) - the report calls it "Delayed speech/language"; HP calls it Delayed speech and language development, and lists "Delayed speech" among its other namesHP:0000729 (1 mention) - the report calls it "Autistic behavior / ASD"; HP calls it Autistic behavior, and lists "Autistic behaviors" among its other namesHP:0000752 (1 mention) - the report calls it "Hyperactivity / ADHD"; HP calls it HyperactivityHP:0000098 (1 mention) - the report calls it "Overgrowth subset: tall stature"; HP calls it Tall stature**HP:0000486 (1 mention) - the report calls it "Eyes: strabismus"; HP calls it Strabismus**HP:0001182 (1 mention) - the report calls it "Limbs/skeletal: tapered fingers"; HP calls it Tapered finger**, and lists "Distally tapering fingers" among its other namesHP:0002019 (1 mention) - the report calls it "Digestive: constipation"; HP calls it Constipation**HP:0000771 (1 mention) - the report calls it "Breast: gynecomastia"; HP calls it Gynecomastia**Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: OMIM, MGI.